Market Cap 6.20B
Revenue (ttm) 806.78M
Net Income (ttm) -363.30M
EPS (ttm) N/A
PE Ratio 8.49
Forward PE 9.20
Profit Margin -45.03%
Debt to Equity Ratio -15.20
Volume 848,400
Avg Vol 1,610,008
Day's Range N/A - N/A
Shares Out 80.29M
Stochastic %K 29%
Beta 0.47
Analysts Sell
Price Target $80.28

Company Profile

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spina...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 222 7000
Fax: 908 222 7231
Address:
500 Warren Corporate Center Drive, Warren, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:57 AM
Actionable Trade Alert for $PTCT: Market Context: $PTCT is currently trading at $77.85, showing a strong position within its recent range. The RSI at 55.56 indicates a neutral to slightly bullish sentiment, suggesting potential for upward movement. The stock is above both the 30-day MA (74.13) and the 50-day MA (70.28), reinforcing a bullish bias. Directional Bias: The recent high of $87.50 and low of $57.47 creates a favorable range for potential gains. The current price is closer to the high, indicating upward momentum. Trade Plan: - Suggested Entry: $78.50 (slightly above the last close) - Stop Loss: $74.00 (to limit downside risk) - Take Profit Targets: 1. $82.00 (5% gain) 2. $85.00 (8.5% gain) 3. $91.00 (17% gain, targeting a significant return) This plan offers a structured approach to capitalize on the upward potential while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:32 PM
Actionable Trade Alert for $PTCT: Market Context: $PTCT is currently trading at $77.85, showing a strong position within its recent range. The RSI at 55.56 indicates a neutral to slightly bullish sentiment, suggesting potential for upward movement. The stock is above both the 30-day MA (74.13) and the 50-day MA (70.28), reinforcing a bullish bias. Directional Bias: The recent high of $87.50 and low of $57.47 creates a favorable range for potential gains. The current price is closer to the high, indicating upward momentum. Trade Plan: - Suggested Entry: $78.50 (slightly above the last close) - Stop Loss: $74.00 (to limit downside risk) - Take Profit Targets: 1. $82.00 (5% gain) 2. $85.00 (8.5% gain) 3. $91.00 (17% gain, targeting a significant return) This plan offers a structured approach to capitalize on the upward potential while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 5 at 2:59 PM
$PTCT Current Stock Price: $76.71 Contracts to trade: $75 PTCT Dec 19 2025 Call Entry: $2.58 Exit: $4.68 ROI: 81% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JasonCO
JasonCO Dec. 4 at 3:35 PM
$PTCT nice bounce from Wed lows
0 · Reply
Quantumup
Quantumup Dec. 3 at 8:15 PM
JonesTrading⬆️ $CAPR's PT to $51 from $29,⬆️PoS to 80%, and reiterated at a Buy rating. $EWTX $PTCT $SRPT Here's what JonesTrading had to say in its note to investors: https://x.com/Quantumup1/status/1996311057824903227?s=20
1 · Reply
Guy8r
Guy8r Dec. 3 at 7:31 PM
$CAPR $PTCT $EWTX $SRPT Wainwright's $60 price target of CAPR based solely on Deramociel, imagine when stealthx, beckers, etc. gets priced in. Multi-bagger potential
1 · Reply
Quantumup
Quantumup Dec. 3 at 7:19 PM
H.C. Wainwright⬆️ $CAPR to $60 from $24, plus⬆️deramiocel's PoS to 90%, while reiterating at a Buy rating. $EWTX $SRPT $PTCT H.C. Wainwright said in its note: We reiterate our Buy rating and are increasing our price target to $60 from $24 based primarily on the following factors: (1) adjusting our fully diluted share count; (2) adjustment to base year; (3) reducing our discount rate to our usual 15% from 30%, which was initially based on the risk surrounding the CRL; and (4) increasing our projected chance of success for deramiocel to 90% from 75%. Our price target is based on our clinical net present value (NPV) model, which is driven entirely by the company's lead asset, deramiocel, in DMD patients. There is no contribution from added deramiocel indications or future potential exosomes candidates, which we believe represent potential upside to our valuation.
0 · Reply
Lunar_Veil_253
Lunar_Veil_253 Dec. 3 at 4:22 PM
$PTCT Forbes used a senior correspondent for the piece not a random contributor and that matters to me because editorial teams choose who gets that slot in front of 140M monthly reach that’s a serious third party filter for a microcap still trading OTC
0 · Reply
hegdaom
hegdaom Dec. 3 at 3:16 PM
0 · Reply
Quantumup
Quantumup Dec. 3 at 3:16 PM
B.Riley reiterated $CAPR at a Buy rating, and places price target under review pending its model update after Capricor Hit its Bull Case Scenario. $PTCT $EWTX $SRPT Here's what B.Riley had to say in its note to investors: https://x.com/Quantumup1/status/1996235575519494466?s=20
1 · Reply
Latest News on PTCT
PTC Therapeutics to Host R&D Day

Nov 20, 2025, 8:00 AM EST - 17 days ago

PTC Therapeutics to Host R&D Day


Here's Why Shares in PTC Therapeutics Soared This Week

Sep 5, 2025, 8:35 AM EDT - 3 months ago

Here's Why Shares in PTC Therapeutics Soared This Week


PTC Therapeutics Stock Is Stuck In A Multi-Year Slump

Aug 21, 2025, 10:00 AM EDT - 3 months ago

PTC Therapeutics Stock Is Stuck In A Multi-Year Slump


PTC Therapeutics, Inc. (PTCT) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 3:19 PM EDT - 4 months ago

PTC Therapeutics, Inc. (PTCT) Q2 2025 Earnings Call Transcript


PTCT Earnings Beat but Sales Drop 4%

Aug 7, 2025, 6:38 PM EDT - 4 months ago

PTCT Earnings Beat but Sales Drop 4%


These Analysts Increase Their Forecasts On PTC Therapeutics

Jul 29, 2025, 11:23 AM EDT - 4 months ago

These Analysts Increase Their Forecasts On PTC Therapeutics


US FDA approves PTC Therapeutics' metabolic disorder drug

Jul 28, 2025, 4:25 PM EDT - 4 months ago

US FDA approves PTC Therapeutics' metabolic disorder drug


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:57 AM
Actionable Trade Alert for $PTCT: Market Context: $PTCT is currently trading at $77.85, showing a strong position within its recent range. The RSI at 55.56 indicates a neutral to slightly bullish sentiment, suggesting potential for upward movement. The stock is above both the 30-day MA (74.13) and the 50-day MA (70.28), reinforcing a bullish bias. Directional Bias: The recent high of $87.50 and low of $57.47 creates a favorable range for potential gains. The current price is closer to the high, indicating upward momentum. Trade Plan: - Suggested Entry: $78.50 (slightly above the last close) - Stop Loss: $74.00 (to limit downside risk) - Take Profit Targets: 1. $82.00 (5% gain) 2. $85.00 (8.5% gain) 3. $91.00 (17% gain, targeting a significant return) This plan offers a structured approach to capitalize on the upward potential while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:32 PM
Actionable Trade Alert for $PTCT: Market Context: $PTCT is currently trading at $77.85, showing a strong position within its recent range. The RSI at 55.56 indicates a neutral to slightly bullish sentiment, suggesting potential for upward movement. The stock is above both the 30-day MA (74.13) and the 50-day MA (70.28), reinforcing a bullish bias. Directional Bias: The recent high of $87.50 and low of $57.47 creates a favorable range for potential gains. The current price is closer to the high, indicating upward momentum. Trade Plan: - Suggested Entry: $78.50 (slightly above the last close) - Stop Loss: $74.00 (to limit downside risk) - Take Profit Targets: 1. $82.00 (5% gain) 2. $85.00 (8.5% gain) 3. $91.00 (17% gain, targeting a significant return) This plan offers a structured approach to capitalize on the upward potential while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 5 at 2:59 PM
$PTCT Current Stock Price: $76.71 Contracts to trade: $75 PTCT Dec 19 2025 Call Entry: $2.58 Exit: $4.68 ROI: 81% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JasonCO
JasonCO Dec. 4 at 3:35 PM
$PTCT nice bounce from Wed lows
0 · Reply
Quantumup
Quantumup Dec. 3 at 8:15 PM
JonesTrading⬆️ $CAPR's PT to $51 from $29,⬆️PoS to 80%, and reiterated at a Buy rating. $EWTX $PTCT $SRPT Here's what JonesTrading had to say in its note to investors: https://x.com/Quantumup1/status/1996311057824903227?s=20
1 · Reply
Guy8r
Guy8r Dec. 3 at 7:31 PM
$CAPR $PTCT $EWTX $SRPT Wainwright's $60 price target of CAPR based solely on Deramociel, imagine when stealthx, beckers, etc. gets priced in. Multi-bagger potential
1 · Reply
Quantumup
Quantumup Dec. 3 at 7:19 PM
H.C. Wainwright⬆️ $CAPR to $60 from $24, plus⬆️deramiocel's PoS to 90%, while reiterating at a Buy rating. $EWTX $SRPT $PTCT H.C. Wainwright said in its note: We reiterate our Buy rating and are increasing our price target to $60 from $24 based primarily on the following factors: (1) adjusting our fully diluted share count; (2) adjustment to base year; (3) reducing our discount rate to our usual 15% from 30%, which was initially based on the risk surrounding the CRL; and (4) increasing our projected chance of success for deramiocel to 90% from 75%. Our price target is based on our clinical net present value (NPV) model, which is driven entirely by the company's lead asset, deramiocel, in DMD patients. There is no contribution from added deramiocel indications or future potential exosomes candidates, which we believe represent potential upside to our valuation.
0 · Reply
Lunar_Veil_253
Lunar_Veil_253 Dec. 3 at 4:22 PM
$PTCT Forbes used a senior correspondent for the piece not a random contributor and that matters to me because editorial teams choose who gets that slot in front of 140M monthly reach that’s a serious third party filter for a microcap still trading OTC
0 · Reply
hegdaom
hegdaom Dec. 3 at 3:16 PM
0 · Reply
Quantumup
Quantumup Dec. 3 at 3:16 PM
B.Riley reiterated $CAPR at a Buy rating, and places price target under review pending its model update after Capricor Hit its Bull Case Scenario. $PTCT $EWTX $SRPT Here's what B.Riley had to say in its note to investors: https://x.com/Quantumup1/status/1996235575519494466?s=20
1 · Reply
Quantumup
Quantumup Dec. 3 at 1:45 PM
TD Cowen Named $IONS a 2026 Best Idea, reiterated at a Buy, a $99 PT and said, Best Ideas 2026: New Launches And Key Pipeline Catalysts To Drive Upside $ARWR $TAK BCRX NVS $RHHBY - $PTCT TD Cowen added, We see robust sales growth in FY26 driven by Tryngolza in sHTG, Dawnzera in HAE, zilganersen in AxD, and incremental Spinraza growth. Key Ph3 data in '26 include Wainua in TTR-CM (H2) & pelacarsen in Lp(a) (H1). We see upside from overlooked catalysts: Ph3 bepi in HBV (H1), Ph2 BIIB080 in AD (mid-'26). RARE's GTX-102 Ph3 in Angelman (H2) should clarify ION582's future in this multi-$ B market.
0 · Reply
dgbio
dgbio Dec. 2 at 8:12 PM
$PTCT R&D Day: • Parkinson's, Phase 1 initiation planned for H2 2026 • PTC612, NLRP3 inhibitor, Pulmonary Inflammation, Phase 1 study initiation planned for H1 2026 • PTC844, DHODH inhibitor, Immunology, expect to initiate Phase 2A PK/PD study in mid-2026.
0 · Reply
dgbio
dgbio Dec. 2 at 7:53 PM
$PTCT R&D Day: • MSH3 Program (Huntington, DM1), Phase 1 ready expected late 2026 • SCA3 Program, Phase 1 ready expected late 2026 • Oncology Program, clinical candidate selection planned for early 2026 • Neurodegeneration, program objective is to have a single therapy with broad utility across multiple disorders.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 7:44 PM
$PTCT $PTF $PTGX $PTH $PTIR Undeniable Accuracy Cycle Trading Signal plugged into AI 🔥 lists 🔥 Math don't lie 🔥
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 1 at 4:29 PM
0 · Reply
JarvisFlow
JarvisFlow Dec. 1 at 2:24 PM
RBC Capital has updated their rating for PTC Therapeutics ( $PTCT ) to Sector Perform with a price target of 91.
0 · Reply
TraceBusta
TraceBusta Nov. 29 at 3:18 PM
$PTCT Very solid upside target can be generated on the 10% PnF chart.
0 · Reply
Estimize
Estimize Nov. 26 at 9:00 PM
Wall St is expecting -0.41 EPS for $PTCT Q4 [Reporting 02/24 AMC] http://www.estimize.com/intro/ptct?chart=historical&metric_name=eps&utm_c
0 · Reply
OptionRunners
OptionRunners Nov. 26 at 4:59 PM
$PTCT Buyer of the March 20th 2026 $90 calls 1,000 times for $6.50
1 · Reply
kindness123
kindness123 Nov. 25 at 6:25 PM
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 23 at 3:56 PM
0 · Reply
danaos
danaos Nov. 18 at 12:51 AM
$PTCT Overweight
0 · Reply